BACKGROUND: Primary pneumonic plague is rare among humans, but treatment efficacy may be tested in appropriate animal models under the FDA 'Animal Rule'. METHODS: Ten African Green monkeys (AGMs) inhaled 44-255 LD(50) doses of aerosolized Yersinia pestis strain CO92. Continuous telemetry, arterial blood gases, chest radiography, blood culture, and clinical pathology monitored disease progression. RESULTS: Onset of fever, >39°C detected by continuous telemetry, 52-80 hours post-exposure was the first sign of systemic disease and provides a distinct signal for treatment initiation. Secondary endpoints of disease severity include tachypnea measured by telemetry, bacteremia, extent of pneumonia imaged by chest x-ray, and serum lactate dehydrogenase enzyme levels. CONCLUSIONS: Inhaled Y. pestis in the AGM results in a rapidly progressive and uniformly fatal disease with fever and multifocal pneumonia, serving as a rigorous test model for antibiotic efficacy studies.
BACKGROUND:Primary pneumonic plague is rare among humans, but treatment efficacy may be tested in appropriate animal models under the FDA 'Animal Rule'. METHODS: Ten African Green monkeys (AGMs) inhaled 44-255 LD(50) doses of aerosolized Yersinia pestis strain CO92. Continuous telemetry, arterial blood gases, chest radiography, blood culture, and clinical pathology monitored disease progression. RESULTS: Onset of fever, >39°C detected by continuous telemetry, 52-80 hours post-exposure was the first sign of systemic disease and provides a distinct signal for treatment initiation. Secondary endpoints of disease severity include tachypnea measured by telemetry, bacteremia, extent of pneumonia imaged by chest x-ray, and serum lactate dehydrogenase enzyme levels. CONCLUSIONS: Inhaled Y. pestis in the AGM results in a rapidly progressive and uniformly fatal disease with fever and multifocal pneumonia, serving as a rigorous test model for antibiotic efficacy studies.
Authors: Frederick Koster; David S Perlin; Steven Park; Trevor Brasel; Andrew Gigliotti; Edward Barr; Leslie Myers; Robert C Layton; Robert Sherwood; C R Lyons Journal: Infect Immun Date: 2010-04-12 Impact factor: 3.441
Authors: Jeannette Guarner; Wun-Ju Shieh; Patricia W Greer; Jean-Marc Gabastou; May Chu; Edward Hayes; Kurt B Nolte; Sherif R Zaki Journal: Am J Clin Pathol Date: 2002-02 Impact factor: 2.493
Authors: James W Boles; M Louise M Pitt; Ross D LeClaire; Paul H Gibbs; Robert G Ulrich; Sina Bavari Journal: Vaccine Date: 2003-06-20 Impact factor: 3.641
Authors: Elizabeth R Wonderlich; Amy L Caroline; Cynthia M McMillen; Aaron W Walters; Douglas S Reed; Simon M Barratt-Boyes; Amy L Hartman Journal: J Virol Date: 2018-01-17 Impact factor: 5.103
Authors: Robert Colby Layton; William Mega; Jacob D McDonald; Trevor L Brasel; Edward B Barr; Andrew P Gigliotti; Frederick Koster Journal: PLoS Negl Trop Dis Date: 2011-02-08
Authors: Nikolas M Stasulli; Kara R Eichelberger; Paul A Price; Roger D Pechous; Stephanie A Montgomery; Joel S Parker; William E Goldman Journal: mBio Date: 2015-10-13 Impact factor: 7.867
Authors: Elizabeth E Zumbrun; Holly A Bloomfield; John M Dye; Ty C Hunter; Paul A Dabisch; Nicole L Garza; Nicholas R Bramel; Reese J Baker; Roger D Williams; Donald K Nichols; Aysegul Nalca Journal: Viruses Date: 2012-10-15 Impact factor: 5.048